Some researchers believe that the combination of new targeted drugs such as aldosterone receptor antagonists, angiotensin receptor-neprilysin inhibitors, and SGLT2 inhibitors could significantly decrease the risk of death in patients with heart failure. This evidence concerns the gene NR3C2 and heart failure.